8-K: Gilead to Acquire Arcellx for $7.8B, Boosting Cell Therapy

Gilead Sciences will acquire Arcellx for an implied equity value of $7.8 billion, including a $115 cash per share and a $5 contingent value right, to gain full control of the promising anito-cel CAR T-cell therapy for multiple myeloma.

Summary

• Gilead Sciences, Inc. will acquire Arcellx, Inc. in a two-step transaction consisting of a tender offer followed by a merger.
• The offer price is $115.00 per share in cash, plus one contractual contingent value right (CVR) worth $5.00 per CVR.
• The CVR payment is contingent upon cumulative worldwide sales of anito-cel exceeding $6.0 billion on or prior to December 31, 2029.
• The implied equity value of the transaction payable at closing is $7.8 billion.
• Gilead currently owns approximately 11.5% of Arcellx's outstanding common stock.
• The transaction was unanimously approved by both the Gilead and Arcellx Boards of Directors.
• The U.S. Food and Drug Administration (FDA) has accepted the Biologic License Application (BLA) for anito-cel for relapsed or refractory multiple myeloma, with an anticipated Prescription Drug User Fee Act (PDUFA) action date of December 23, 2026.
• The acquisition aims to maximize the long-term potential of anito-cel, accelerate its development and commercialization, and eliminate profit-share, milestones, and royalties from the existing collaboration between Kite (a Gilead company) and Arcellx.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive for Arcellx shareholders due to the substantial premium and the strategic fit for Gilead, enhancing its cell therapy pipeline with a promising multiple myeloma treatment. The CVR adds potential upside, though with inherent risk.

Positives

• The acquisition offers a significant premium of 68% to Arcellx's 30-day volume-weighted average share price as of February 20, 2026.
• Gilead gains full control of anito-cel, a potentially transformative BCMA-directed CAR T-cell therapy for patients with multiple myeloma, enhancing its oncology pipeline.
• The FDA's acceptance of the anito-cel BLA with a PDUFA date of December 23, 2026, provides a clear regulatory pathway and potential market entry.
• The transaction is expected to be accretive to Gilead's earnings per share in 2028 and thereafter, upon FDA approval of anito-cel.
• The acquisition eliminates future profit-share, milestones, and royalties from the existing collaboration, simplifying the financial structure for anito-cel.
• Arcellx's D-Domain CAR technology platform offers potential for next-generation CAR T-cell and bispecific therapies, including in vivo cell therapy efforts, which Gilead can now fully leverage.

Negatives

• The $5.00 CVR payment is contingent on achieving a specific sales milestone ($6.0 billion cumulative worldwide sales by December 31, 2029), and there is no assurance that any CVR payment will be received.
• Arcellx is subject to customary no-shop restrictions, limiting its ability to solicit alternative acquisition proposals, though exceptions exist for bona fide unsolicited superior offers.
• Arcellx would be required to pay Gilead a termination fee of $260,000,000 under specified circumstances, such as terminating the agreement to enter into a superior offer.

Risks

• Uncertainties as to the timing of the Offer and the Merger.
• The risk that the Offer or the Merger may not be completed in a timely manner or at all.
• Uncertainties as to the percentage of Arcellx's stockholders tendering their shares in the Offer.
• The possibility that competing offers or acquisition proposals for Arcellx will be made.
• The possibility that any or all of the various conditions to the consummation of the Offer or the Merger may not be satisfied or waived, including the failure to receive any required regulatory approvals.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the Merger Agreement, including circumstances which would require Arcellx to pay a termination fee.
• The effect of the announcement or pendency of the transactions on Arcellx's ability to retain and hire key personnel, its ability to maintain relationships with its suppliers and others with whom it does business, or its operating results and business generally.
• Risks related to diverting management's attention from Arcellx's ongoing business operations.
• The risk that stockholder litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• The risk that no CVR Payments will be made under the CVR Agreement.
• The possibility of unfavorable results from clinical trials.
• Regulatory applications and related timelines.
• Any assumptions underlying forward-looking statements.

Future Outlook

Gilead anticipates anito-cel could become a foundational treatment for multiple myeloma, including earlier lines of therapy, and its D-domain BCMA binder may strengthen efforts in in vivo cell therapy. The transaction is expected to be accretive to Gilead's earnings per share in 2028 and thereafter, assuming FDA approval.

Management Comments

• "This agreement reflects our conviction in the potential of anito-cel and our intention to move with speed so we can make the most of that potential for patients with multiple myeloma. Beyond the potential launch this year, anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy. In addition, the anito-cel D-domain BCMA binder could be important to our work in in vivo cell therapy, further strengthening our potential in oncology and inflammation." Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences.
• "The story of Arcellx is one of innovation, passion, resilience and teamwork. I could not be prouder of our team, our contribution to the myeloma field, and the impact anito-cel and our D-Domain platform are poised to have for patients and clinicians. We are fortunate to have found a world-class partner in Gilead, which has the expertise to carry forward Arcellx’s legacy. Kite is well-positioned to maximize access to anito-cel, benefiting more patients, and the company’s commitment to be the leader in cell therapy is one I admire. I’m grateful to our Board of Directors for this opportunity, our shareholders who supported our journey, our partners who believed in us, the patients and physicians who participated in our studies, and most of all, our team members who did the impossible and left an indelible mark on the future of medicine." Rami Elghandour, Chairman and Chief Executive Officer, Arcellx.

Industry Context

StockSavvy.ai notes that this acquisition solidifies Gilead's position in the rapidly evolving cell therapy market, particularly in oncology. By gaining full control of anito-cel, a promising BCMA-directed CAR T-cell therapy, Gilead (through its Kite company) aims to accelerate its development and commercialization in the competitive multiple myeloma treatment landscape. This move aligns with broader industry trends of consolidation and strategic investments in advanced therapeutic modalities, leveraging Arcellx's innovative D-Domain CAR technology platform for potential future applications beyond anito-cel.

Comparison to Industry Standards

• The $115 cash per share represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of February 20, 2026, which is a substantial premium compared to typical biotech acquisitions, reflecting the strategic value of anito-cel and its platform.
• The contingent value right (CVR) structure, tied to cumulative global net sales of anito-cel reaching $6.0 billion by year-end 2029, is a common mechanism in biotech M&A to bridge valuation gaps and share future commercial success, similar to CVRs seen in other large pharmaceutical acquisitions of clinical-stage companies.
• Gilead's existing collaboration with Arcellx through Kite Pharma, Inc. (dated December 8, 2022) provided a pre-existing framework for co-development and co-commercialization, making this full acquisition a natural progression to streamline operations and maximize the asset's potential, a strategy often employed by larger pharmaceutical companies with successful collaboration partners.

Management Changes

Corporate Governance

Legal Proceedings

• The filing notes the risk of stockholder litigation in connection with the transactions contemplated by the Merger Agreement, which may result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• Gilead Sciences, Inc. currently owns approximately 11.5% of Arcellx's outstanding common stock.
• Kite Pharma, Inc., a Gilead company, has an existing Collaboration and License Agreement with Arcellx, Inc. dated December 8, 2022, for the co-development and co-commercialization of anito-cel.

Stakeholder Impact

• Shareholders of Arcellx will receive a substantial premium for their shares, plus a contingent value right, providing a favorable return on investment.
• Employees of Arcellx will be provided with comparable target cash opportunity and broad-based employee benefits for a period, with credit for prior service for certain benefits, though employment remains at-will.
• Patients with multiple myeloma may benefit from accelerated development and commercialization of anito-cel due to Gilead's full control and resources.
• Suppliers and partners may experience changes in relationships as Arcellx integrates into Gilead's operations, though efforts will be made to preserve satisfactory business relationships.
• Creditors' obligations will transfer to the Surviving Corporation, which will be a wholly-owned subsidiary of Gilead.

Next Steps

• Purchaser (Gilead subsidiary) will commence a tender offer within 10 business days of February 22, 2026.
• The tender offer will remain open for a minimum of 20 business days.
• The closing of the merger is anticipated during the second quarter of 2026.
• The FDA PDUFA action date for anito-cel BLA is December 23, 2026.
• Arcellx will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• Gilead will file a Tender Offer Statement on Schedule TO with the SEC.
• Arcellx will terminate the Sales Agreement within five business days of February 22, 2026.
• Arcellx will use commercially reasonable efforts to cause its CEO to enter into a non-competition agreement with Parent prior to the Closing Date.

Key Dates

Recommendation

The acquisition price offers a substantial premium to Arcellx shareholders, indicating a strong valuation for the company's assets, particularly anito-cel. The additional CVR provides further upside potential tied to the commercial success of the product. For existing shareholders, tendering shares appears to be a clear path to realizing significant value. For investors considering Arcellx, the tender offer price sets a floor with potential CVR upside, making it an attractive short-term opportunity, assuming the deal closes as expected.

Keywords

Arcellx, Gilead Sciences, Acquisition, Merger, CAR T-cell therapy, anito-cel, multiple myeloma, biotechnology, pharmaceuticals, BCMA-directed therapy, contingent value right, tender offer, FDA approval, PDUFA, oncology, cell therapy platform, D-Domain CAR technology